Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/9525
Full metadata record
DC FieldValueLanguage
dc.contributor.authorJakovljevic, Mihajlo-
dc.contributor.authorMijailovic, Zeljko-
dc.contributor.authorPopovska Jovicic, Biljana-
dc.contributor.authorČANOVIĆ, Predrag-
dc.contributor.authorGajovic, Olgica-
dc.contributor.authorJovanovic, Mirjana-
dc.contributor.authorPetrovic, Dejan-
dc.contributor.authorMilovanovic, Olivera-
dc.contributor.authorĐorđević, Nataša-
dc.date.accessioned2020-09-19T18:30:22Z-
dc.date.available2020-09-19T18:30:22Z-
dc.date.issued2013-01-01-
dc.identifier.issn1735143X-
dc.identifier.urihttps://scidar.kg.ac.rs/handle/123456789/9525-
dc.description.abstract© 2013, Kowsar Corp.; Published by Kowsar Corp. Background: Pegylated interferon alfa plus ribavirin protocol is currently considered the most efficient hepatitis C treatment. However, no evidence of costs comparison among common viral genotypes has been published. Objectives: We aimed to assess core drivers of hepatitis C medical care costs and compare cost effectiveness of this treatment among patients infected by hepatitis C virus with genotypes 1 or 4 (group I), and 2 or 3 (group II). Patients and Materials: Prospective bottom-up cost-effectiveness analysis from societal perspective was conducted at Infectious Diseases Clinic, University Clinic Kragujevac, Serbia, from 2007 to 2010. There were 81 participants with hepatitis C infection, treated with peg alpha-2a interferon plus ribavirin for 48 or 24 weeks. Economic data acquired were direct inpatient medical costs, outpatient drug acquisition costs, and indirect costs calculated through human capital approach. Results: Total costs were significantly higher (P = 0.035) in group I (mean ± SD: 12,751.54 ± 5,588.06) compared to group II (mean ± SD: 10,580.57 ± 3,973.02). In addition, both direct (P = 0.039) and indirect (P < 0.001) costs separately were significantly higher in group I compared to group II. Separate comparison within direct costs revealed higher total cost of medical care (P = 0.024) in first compared to second genotype group, while the similar tendency was observed for total drug acquisition (P = 0.072). Conclusion: HCV genotypes 1 and 4 cause more severe clinical course require more care and thus incur higher expenses compared to HCV 2 and 3 genotypes. Policy makers should consider willingness to pay threshold differentially depending upon HCV viral genotype detected.-
dc.relation.ispartofHepatitis Monthly-
dc.titleAssessment of viral genotype impact to the cost-effectiveness and overall costs of care for peg-interferon-2α + ribavirine treated chronic hepatitis C patients-
dc.typejournal article-
dc.identifier.doi10.5812/hepatmon.6750-
dc.identifier.scopus85006226925-
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

62

Downloads(s)

5

Files in This Item:
File Description SizeFormat 
10.5812-hepatmon.6750.pdf400.69 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.